CLN-049 Enters a Potentially Registrational AML Study

Company Cullinan Therapeutics Event Type First patient dosed in potentially registrational Phase 2 Modality Bispecific T-cell engager (FLT3 x CD3) Asset CLN-049 Target FLT3 (wild-type and mutant) and CD3 epsilon Disease Area Relapsed or refractory acute myeloid leukemia; newly diagnosed TP53-mutated AML (exploratory) Summary Cullinan…